Search

everythinglearnresearchcommunity

for

Search:↓

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Breezula, a potential hair loss treatment, is still in trials with no recent updates on its release, while its acne version, Winlevi, is available but expensive. Users discuss the high cost of hair loss treatments and alternatives like Minoxidil and topical Finasteride.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

People are discussing Breezula, a hair loss treatment, with mixed opinions on its value for the cost. Some are interested in it, while others think it's not worth the money.

The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.

People are discussing the effectiveness of Breezula for hair loss maintenance. Some individuals are using Breezula alone, avoiding finasteride, and one plans to use Breezula after a hair transplant.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

The conversation is about expecting results from Breezula, a hair loss treatment, with no new information released as of April 1st. Some joked it's just onion juice, while another comment suggested a conspiracy to cause baldness.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

The conversation is about updates on hair loss treatments Breezula or PTD-DBM. No new information was provided.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

The conversation is about someone wanting to import RU58841 or CB-03-01 from China for hair loss treatment but being concerned about receiving counterfeit products. Specific treatments mentioned are RU58841 and CB-03-01.

The user follows an intensive hair loss protocol including dutasteride, biotin, black tea, pumpkin seed oil, peppermint shampoo, rosemary conditioner, mukemame, soy milk, lycopene, garlic, magnesium, chamomile, spicy food, citrus bergamot, zinc, multivitamins, kefir, and Greek yogurt. They plan to alternate between pumpkin seed oil and safflower oil and will share before and after pictures.